First generation antipsychotics are the original class of medications developed to treat psychosis, primarily by blocking dopamine receptors in the brain. Introduced in the early 1950s, they remain widely used today for schizophrenia, bipolar mania, and several non-psychiatric conditions. They’re also called “typical” antipsychotics or neuroleptics, distinguishing them from the “atypical” second generation drugs that arrived decades later.
How They Work
These medications reduce psychotic symptoms by blocking a specific type of dopamine receptor called D2. They’re most effective when they block roughly 72% of D2 receptors in the brain, which is enough to dampen the overactive dopamine signaling that drives hallucinations and delusions. But dopamine isn’t the only system they affect. First generation antipsychotics also interfere with receptors involved in alertness, muscle control, and the body’s fight-or-flight response, which explains many of their side effects.
The very first antipsychotic, chlorpromazine, was synthesized in 1951 by a French pharmaceutical company. A military surgeon named Henri Laborit noticed its powerful calming effects during anesthesia research and recognized its potential for psychiatry. The first psychiatric patient to receive it was a 24-year-old man in a severe manic episode, treated in January 1952. Within a few years, chlorpromazine transformed psychiatric care worldwide and earned Laborit an Albert Lasker Award.
High Potency vs. Low Potency
First generation antipsychotics split into two broad groups based on how much of the drug is needed to achieve a therapeutic effect.
High potency drugs work at low doses, typically 1 to 10 milligrams. This group includes haloperidol, fluphenazine, trifluoperazine, perphenazine, thiothixene, loxapine, and pimozide. Because they bind tightly and selectively to dopamine receptors, they cause less sedation and fewer problems like dry mouth or dizziness. The tradeoff is a higher risk of movement-related side effects.
Low potency drugs require much larger doses, often in the hundreds of milligrams. Chlorpromazine and thioridazine are the main examples. These medications block a wider range of receptors beyond dopamine, which makes them more sedating and more likely to cause dry mouth, constipation, urinary retention, and drops in blood pressure. They do, however, carry a lower risk of the stiff, involuntary movements that high potency drugs can trigger.
What They’re Used For
Schizophrenia is the most common indication across the entire class. Nearly every first generation antipsychotic carries an FDA approval for it. Beyond that, the approved uses vary by drug. Chlorpromazine has one of the broadest profiles: schizophrenia, bipolar mania, hyperactivity, severe nausea and vomiting, and even intractable hiccups. Haloperidol and pimozide are both approved for Tourette’s disorder. Prochlorperazine and droperidol are primarily used as anti-nausea medications, sometimes in people who have no psychiatric condition at all.
Several of these drugs are also available as long-acting injections, sometimes called depot formulations. Haloperidol decanoate, flupentixol decanoate, and zuclopenthixol decanoate can be given as infrequently as once every four weeks. These are particularly useful when someone has difficulty taking daily pills consistently, since a single injection provides steady medication levels for weeks.
How They Compare to Newer Antipsychotics
A common assumption is that second generation antipsychotics are more effective, but large meta-analyses tell a different story. When researchers pooled data from trials involving nearly 2,000 patients experiencing a first episode of psychosis, there was no significant difference between the two classes in reducing positive symptoms like hallucinations and delusions. Overall symptom improvement, depression scores, and treatment response rates were also similar. Only two individual second generation drugs (olanzapine and amisulpride) showed any edge over first generation drugs in total symptom reduction, and even then the advantage was modest.
The real differences between the classes are in their side effect profiles rather than their effectiveness. First generation drugs cause more movement problems; second generation drugs are more likely to cause weight gain and metabolic changes.
Movement-Related Side Effects
The most well-known downside of first generation antipsychotics is their effect on movement, collectively called extrapyramidal symptoms. These happen because the same dopamine pathways that control psychotic symptoms also help regulate motor function.
- Parkinsonism causes tremor, stiffness, and shuffling gait similar to Parkinson’s disease. It’s the most common movement side effect, occurring in an estimated 37 to 44% of patients annually.
- Akathisia is an intense, distressing sense of inner restlessness and an inability to sit still. Annual rates range from 26 to 35%.
- Tardive dyskinesia involves repetitive, involuntary movements, often of the face and tongue (lip smacking, grimacing, tongue thrusting). The annualized incidence with first generation drugs is about 6.5%, compared to 2.6% with second generation drugs. Because the risk is cumulative, it compounds with each year of treatment, especially during the first five years. Older adults are particularly vulnerable and can develop it after as little as one month of use.
- Dystonia causes sudden, sustained muscle contractions that can twist the neck, jaw, or eyes into abnormal positions. It tends to appear early in treatment.
Because tardive dyskinesia can become permanent, monitoring is essential. The standard screening tool is the Abnormal Involuntary Movement Scale (AIMS), a brief physical exam that checks for involuntary movements in the face, limbs, and trunk. Current American Psychiatric Association guidelines recommend AIMS screening every six months for people at high risk and every twelve months for others. Ideally, a baseline exam happens before starting the medication so any later changes can be detected accurately.
Hormonal Effects
By blocking dopamine receptors in the pituitary gland, first generation antipsychotics frequently raise levels of the hormone prolactin. Up to 70% of patients with schizophrenia on antipsychotics develop elevated prolactin, with roughly 60% of women and 40% of men exceeding normal levels. In some cases, prolactin rises to ten times the baseline.
The practical consequences can significantly affect quality of life. In women, the most commonly reported symptoms are breast pain (about 55%), irregular periods (20%), missed periods (14%), and milky discharge from the breasts (around 10%). Men can experience breast tissue growth and sexual dysfunction. Over the long term, persistently high prolactin may reduce bone density and has been linked in some studies to a higher risk of breast cancer and infertility.
Neuroleptic Malignant Syndrome
The most dangerous potential reaction to any antipsychotic is neuroleptic malignant syndrome, a rare but life-threatening emergency. It involves three hallmark features: severe muscle rigidity, high fever, and a clear link to a dopamine-blocking medication. Beyond those core signs, a person may also develop a rapid heart rate, unstable blood pressure, heavy sweating, difficulty swallowing, tremor, confusion, or inability to speak. This is a medical emergency requiring immediate treatment, and it can develop at any point during therapy, not just when starting a new medication.
Other Common Side Effects
Beyond movement and hormonal effects, first generation antipsychotics can cause sedation and drowsiness (especially low potency drugs), weight gain, drops in blood pressure when standing up, and a range of effects from blocking the body’s acetylcholine system: dry mouth, blurred vision, constipation, and difficulty urinating. Some of these side effects are actually dose-limiting, meaning they determine the maximum amount a person can comfortably take. High potency drugs tend to cause fewer of these general side effects but more movement problems, while low potency drugs flip that pattern.